Neumora Therapeutics, Inc. (NasdaqGS: NMRA)
Health Care · Pharmaceuticals · US
$1.63
+1.87% today · -2.4% 1Y
Neumora Therapeutics, Inc. (NasdaqGS: NMRA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $300.63M and employs 92 people.
Over the last twelve months the share price has lost 2.4%, trading between 0.83 and 3.65.
Tweenvest scores Neumora Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
NMRA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $300.63M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.22
- Dividend yield
- —
- Beta (5Y)
- 2.78
- 52-week high
- $3.65
- 52-week low
- $0.83
- Avg volume (3M)
- —
- Shares outstanding
- 187.90M
- Employees
- 92
- Next earnings
- —
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
- Founded
- 2019
- Listed since
- Sep 15, 2023
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.22 | -0.96% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.15 | +0.29% |
Figures last refreshed Aug 18, 2026.